IMMUNE NETWORK

  • 제13권6호
  • /
  • Pages.257-263
  • /
  • 2013
  • /
  • 1598-2629(pISSN)
  • /
  • 2092-6685(eISSN)
대한면역학회 (The Korean Association of Immunobiologists)
권호 표지
DOI QR코드

DOI QR Code

CP-690550 Treatment Ameliorates Established Disease and Provides Long-Term Therapeutic Effects in an SKG Arthritis Model

  • Oh, Keunhee (Laboratory of Immunology, Department of Biomedical Sciences, Seoul National University College of Medicine) ;
  • Seo, Myung Won (Laboratory of Immunology, Department of Biomedical Sciences, Seoul National University College of Medicine) ;
  • Kim, In Gyu (Laboratory of Immunology, Department of Biomedical Sciences, Seoul National University College of Medicine) ;
  • Hwang, Young-Il (Laboratory of Immunology, Department of Anatomy, Seoul National University College of Medicine) ;
  • Lee, Hee-Yoon (Department of Chemistry, KAIST) ;
  • Lee, Dong-Sup (Laboratory of Immunology, Department of Biomedical Sciences, Seoul National University College of Medicine)
  • 투고 : 2013.10.01
  • 심사 : 2013.10.24
  • 발행 : 2013.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Although pathogenesis of human rheumatoid arthritis (RA) remains unclear, arthritogenic T cells and downstream signaling mediators have been shown to play critical roles. An increasing numbers of therapeutic options have been added for the effective control of RA. Nevertheless, there is still a category of patients that fails treatment and suffers from progressive disease. The recently developed immunosuppressant CP-690550, a small molecule JAK kinase inhibitor, has been implicated as an important candidate treatment modality for autoimmune arthritis. In this study, we evaluated the therapeutic effect of CP-690550 on established arthritis using an SKG arthritis model, a pathophysiologically relevant animal model for human RA. CP-690550 treatment revealed remarkable long-term suppressive effects on SKG arthritis when administered to the well-advanced disease (clinical score 3.5~4.0). The treatment effect lasted at least 3 more weeks after cessation of drug infusion, and suppression of disease was correlated with the reduced pro-inflammatory cytokines, including IL-17, IFN-${\gamma}$, and IL-6 and increased level of immunoregulatory IL-10.

키워드

참고문헌

  1. Firestein, G. S. 2005. Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J. Clin. Rheumatol. 11: S39-S44. https://doi.org/10.1097/01.rhu.0000166673.34461.33
  2. VanderBorght, A., P. Geusens, J. Raus, and P. Stinissen. 2001. The autoimmune pathogenesis of rheumatoid arthritis: role of autoreactive T cells and new immunotherapies. Semin. Arthritis Rheum. 31: 160-175. https://doi.org/10.1053/sarh.2001.27736
  3. McInnes, I. B. and G. Schett. 2007. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7: 429-442. https://doi.org/10.1038/nri2094
  4. Firestein, G. S. 2003. Evolving concepts of rheumatoid arthritis. Nature 423: 356-361. https://doi.org/10.1038/nature01661
  5. Fournier, C. 2005. Where do T cells stand in rheumatoid arthritis? Joint Bone Spine 72: 527-532. https://doi.org/10.1016/j.jbspin.2004.12.012
  6. Brand, D. D., A. H. Kang, and E. F. Rosloniec. 2003. Immunopathogenesis of collagen arthritis. Springer Semin. Immunopathol. 25: 3-18. https://doi.org/10.1007/s00281-003-0127-1
  7. Klareskog, L. and H. McDevitt. 1999. Rheumatoid arthritis and its animal models: the role of TNF-alpha and the possible absence of specific immune reactions. Curr. Opin. Immunol. 11: 657-662. https://doi.org/10.1016/S0952-7915(99)00033-3
  8. Horai, R., A. Nakajima, K. Habiro, M. Kotani, S. Nakae, T. Matsuki, A. Nambu, S. Saijo, H. Kotaki, K. Sudo, A. Okahara, H. Tanioka, T. Ikuse, N. Ishii, P. L. Schwartzberg, R. Abe, and Y. Iwakura. 2004. TNF-alpha is crucial for the development of autoimmune arthritis in IL-1 receptor antagonist- deficient mice. J. Clin. Invest. 114: 1603-1611. https://doi.org/10.1172/JCI20742
  9. Hata, H., N. Sakaguchi, H. Yoshitomi, Y. Iwakura, K. Sekikawa, Y. Azuma, C. Kanai, E. Moriizumi, T. Nomura, T. Nakamura, and S. Sakaguchi. 2004. Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J. Clin. Invest. 114: 582-588. https://doi.org/10.1172/JCI200421795
  10. Ferrari-Lacraz, S., E. Zanelli, M. Neuberg, E. Donskoy, Y. S. Kim, X. X. Zheng, W. W. Hancock, W. Maslinski, X. C. Li, T. B. Strom, and T. Moll. 2004. Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis. J. Immunol. 173: 5818-5826. https://doi.org/10.4049/jimmunol.173.9.5818
  11. Gracie, J. A., R. J. Forsey, W. L. Chan, A. Gilmour, B. P. Leung, M. R. Greer, K. Kennedy, R. Carter, X. Q. Wei, D. Xu, M. Field, A. Foulis, F. Y. Liew, and I. B. McInnes. 1999. A proinflammatory role for IL-18 in rheumatoid arthritis. J. Clin. Invest. 104: 1393-1401. https://doi.org/10.1172/JCI7317
  12. Nakae, S., A. Nambu, K. Sudo, and Y. Iwakura. 2003. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J. Immunol. 171: 6173-6177. https://doi.org/10.4049/jimmunol.171.11.6173
  13. Lubberts, E., M. I. Koenders, B. Oppers-Walgreen, L. van den Bersselaar, C. J. Coenen-de Roo, L. A. Joosten, and W. B. van den Berg. 2004. Treatment with a neutralizing anti- murine interleukin-17 antibody after the onset of collagen- induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum. 50: 650-659. https://doi.org/10.1002/art.20001
  14. Murphy, C. A., C. L. Langrish, Y. Chen, W. Blumenschein, T. McClanahan, R. A. Kastelein, J. D. Sedgwick, and D. J. Cua. 2003. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 198: 1951-1957. https://doi.org/10.1084/jem.20030896
  15. Hirota, K., M. Hashimoto, H. Yoshitomi, S. Tanaka, T. Nomura, T. Yamaguchi, Y. Iwakura, N. Sakaguchi, and S. Sakaguchi. 2007. T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-$17^+$ Th cells that cause autoimmune arthritis. J. Exp. Med. 204: 41-47. https://doi.org/10.1084/jem.20062259
  16. Lubberts, E., M. I. Koenders, and W. B. van den Berg. 2005. The role of T-cell interleukin-17 in conduction destructive arthritis: lessons from animal models. Arthritis Res. Ther. 7: 29-37. https://doi.org/10.1186/ar1478
  17. Changelian, P. S., M. E. Flanagan, D. J. Ball, C. R. Kent, K. S. Magnuson, W. H. Martin, B. J. Rizzuti, P. S. Sawyer, B. D. Perry, W. H. Brissette, S. P. McCurdy, E. M. Kudlacz, M. J. Conklyn, E. A. Elliott, E. R. Koslov, M. B. Fisher, T. J. Strelevitz, K. Yoon, D. A. Whipple, J. Sun, M. J. Munchhof, J. L. Doty, J. M. Casavant, T. A. Blumenkopf, M. Hines, M. F. Brown, B. M. Lillie, C. Subramanyam, C. Shang-Poa, A. J. Milici, G. E. Beckius, J. D. Moyer, C. Su, T. G. Woodworth, A. S. Gaweco, C. R. Beals, B. H. Littman, D. A. Fisher, J. F. Smith, P. Zagouras, H. A. Magna, M. J. Saltarelli, K. S. Johnson, L. F. Nelms, S. G. Des Etages, L. S. Hayes, T. T. Kawabata, D. Finco-Kent, D. L. Baker, M. Larson, M. S. Si, R. Paniagua, J. Higgins, B. Holm, B. Reitz, Y. J. Zhou, R. E. Morris, J. J. O'Shea, and D. C. Borie. 2003. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302: 875-878. https://doi.org/10.1126/science.1087061
  18. Kudlacz, E., B. Perry, P. Sawyer, M. Conklyn, S. McCurdy, W. Brissette, M. Flanagan, and P. Changelian. 2004. The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am. J. Transplant. 4: 51-57.
  19. Borie, D. C., P. S. Changelian, M. J. Larson, M. S. Si, R. Paniagua, J. P. Higgins, B. Holm, A. Campbell, M. Lau, S. Zhang, M. G. Flores, G. Rousvoal, J. Hawkins, D. A. Ball, E. M. Kudlacz, W. H. Brissette, E. A. Elliott, B. A. Reitz, and R. E. Morris. 2005. Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in Nonhuman Primates. Transplantation 79: 791-801. https://doi.org/10.1097/01.TP.0000157117.30290.6F
  20. Paniagua, R., M. S. Si, M. G. Flores, G. Rousvoal, S. Zhang, O. Aalami, A. Campbell, P. S. Changelian, B. A. Reitz, and D. C. Borie. 2005. Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in Nonhuman Primate recipients of kidney allografts. Transplantation 80: 1283-1292. https://doi.org/10.1097/01.tp.0000177643.05739.cd
  21. Park, H. B., K. Oh, N. Garmaa, M. W. Seo, O. J. Byoun, H. Y. Lee, and D. S. Lee. 2010. CP-690550, a Jak inhibitor, suppresses $CD4^+$ T cell-mediated acute graft-versus-host disease by inhibiting the IFN-g pathway. Transplantation 90: 825-835.
  22. Ghoreschi, K., M. I. Jesson, X. Li, J. L. Lee, S. Ghosh, J. W. Alsup, J. D. Warner, M. Tanaka, S. M. Steward-Tharp, M. Gadina, C. J. Thomas, J. C. Minnerly, C. E. Storer, T. P. LaBranche, Z. A. Radi, M. E. Dowty, R. D. Head, D. M. Meyer, N. Kishore, and J. J. O'Shea. 2011. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J. Immunol. 186: 4234-4243. https://doi.org/10.4049/jimmunol.1003668
  23. Tak, P. P. and J. R. Kalden. 2011. Advances in rheumatology: new targeted therapeutics. Arthritis Res. Ther. 13(Suppl 1): S5.
  24. Flanagan, M. E., T. A. Blumenkopf, W. H. Brissette, M. F.Brown, J. M. Casavant, C. Shang-Poa, J. L. Doty, E. A. Elliott, M. B. Fisher, M. Hines, C. Kent, E. M. Kudlacz, B. M. Lillie, K. S. Magnuson, S. P. McCurdy, M. J. Munchhof, B. D. Perry, P. S. Sawyer, T. J. Strelevitz, C. Subramanyam, J. Sun, D. A. Whipple, and P. S. Changelian. 2010. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J. Med. Chem. 53: 8468-8484. https://doi.org/10.1021/jm1004286
  25. West, K. 2009. CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. Curr. Opin. Investig. Drugs 10: 491-504.
  26. Milici, A. J., E. M. Kudlacz, L. Audoly, S. Zwillich, and P. Changelian. 2008. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res. Ther. 10: R14. https://doi.org/10.1186/ar2365
  27. Sakaguchi, N., T. Takahashi, H. Hata, T. Nomura, T. Tagami, S. Yamazaki, T. Sakihama, T. Matsutani, I. Negishi, S. Nakatsuru, and S. Sakaguchi. 2003. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 426: 454-460. https://doi.org/10.1038/nature02119
  28. Yoshitomi, H., N. Sakaguchi, K. Kobayashi, G. D. Brown, T. Tagami, T. Sakihama, K. Hirota, S. Tanaka, T. Nomura, I. Miki, S. Gordon, S. Akira, T. Nakamura, and S. Sakaguchi. 2005. A role for fungal {beta}-glucans and their receptor Dectin-1 in the induction of autoimmune arthritis in genetically susceptible mice. J. Exp. Med. 201: 949-960. https://doi.org/10.1084/jem.20041758
  29. Sakaguchi, S., N. Sakaguchi, H. Yoshitomi, H. Hata, T. Takahashi, and T. Nomura. 2006. Spontaneous development of autoimmune arthritis due to genetic anomaly of T cell signal transduction: Part 1. Semin. Immunol. 18: 199-206. https://doi.org/10.1016/j.smim.2006.03.007
  30. Oh, K., K. M. Joo, Y. S. Jung, J. Lee, H. Kang, H. Y. Lee, and D. S. Lee. 2010. A receptor-independent, cell-based JAK activation assay for screening for JAK3-specific inhibitors. J. Immunol. Methods 354: 45-52. https://doi.org/10.1016/j.jim.2010.01.010
  31. Asadullah, K., R. Sabat, M. Friedrich, H. D. Volk, and W. Sterry. 2004. Interleukin-10: an important immunoregulatory cytokine with major impact on psoriasis. Curr. Drug Targets Inflamm. Allergy 3: 185-192. https://doi.org/10.2174/1568010043343886
  32. You, S., M. A. Alyanakian, B. Segovia, D. Damotte, J. Bluestone, J. F. Bach, and L. Chatenoud. 2008. Immunoregulatory pathways controlling progression of autoimmunity in NOD mice. Ann. N. Y. Acad. Sci. 1150: 300-310. https://doi.org/10.1196/annals.1447.046
  33. Cope, A. P., H. Schulze-Koops, and M. Aringer. 2007. The central role of T cells in rheumatoid arthritis. Clin. Exp. Rheumatol. 25: S4-11.
  34. Podojil, J. R. and S. D. Miller. 2009. Molecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy. Immunol. Rev. 229: 337-355. https://doi.org/10.1111/j.1600-065X.2009.00773.x
  35. Appel, S. and P. Brossart. 2007. Development of novel compounds to treat autoimmune and inflammatory diseases and graft versus host reactions. Endocr. Metab. Immune Disord. Drug Targets 7: 93-97. https://doi.org/10.2174/187153007780832073

피인용 문헌

  1. Old and new therapeutics for Rheumatoid Arthritis:in vivomodels and drug development vol.38, pp.1, 2013, https://doi.org/10.3109/08923973.2015.1125917
  2. Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies vol.11, pp.None, 2013, https://doi.org/10.3389/fimmu.2020.591176